drugset / Trial / NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT06921928 ↗

Phase 1/2 Recruiting 117 enrolled AstraZeneca
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

Timeline

Start
2025-04-29
Primary completion
2027-03-31
Completion
2027-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4360 Unknown — —